Biblio Discovery — Demo Discovery Service

10 hasil untuk "Jacques Raphael"

Menampilkan 1–10 · 0,79 detik · RSS

  1. Artikel Jurnal Teks lengkap

    ‘Targeting’ Improved Outcomes with Antibody-Drug Conjugates in Non-Small Cell Lung Cancer—An Updated Review

    Saurav Verma; Daniel Breadner; Jacques Raphael

    Current Oncology, Vol. 30 No. 4 · 2023 · Inggris · DOAJ Scopus

    Antibody-Drug conjugates (ADCs) are a relatively new class of drugs with a promise to improve the outcomes in specific cancers. By delivering the cytotoxic agent to tumor cells expressing specific antigens, ADCs achieve a better therapeutic index and more potency. ADCs have been approved for…

  2. Artikel Jurnal Teks lengkap

    Durable Response to Atezolizumab in Extensive-Stage Small-Cell Lung Cancer Leading to 60 Months Overall Survival: A Case Report

    Freeman Paczkowski; Jacques Raphael; Claire Browne

    Current Oncology, Vol. 31 No. 7 · 2024 · Inggris · DOAJ Scopus

    Small-cell lung cancer (SCLC) remains a disease with poor prognosis, particularly in extensive-stage SCLC (ES-SCLC). Current standard-of-care treatment includes chemotherapy with platinum agents and etoposide plus immunotherapy with atezolizumab or durvalumab, which has achieved a mean overall…

  3. Artikel Jurnal

    Antibody–drug conjugates versus docetaxel for previously treated advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomized controlled trials

    Saqib Raza Khan; Laís Marques Eiras; Gabriel Boldt dkk.

    Therapeutic Advances in Medical Oncology, Vol. 17 · 2025 · Inggris · DOAJ Scopus

    Background: Docetaxel, following progression on immunotherapy and platinum-based chemotherapy, remains the standard of care for advanced non-small-cell lung cancer (NSCLC) but offers limited promise. Antibody–drug conjugates (ADCs) may improve outcomes in this population. Objectives: Data from the…

  4. Artikel Jurnal

    Early mortality in patients with cancer and COVID-19 infection treated with immunotherapy

    Jacques Raphael; Britney Le; Simron Singh dkk.

    BMC Cancer, Vol. 25 No. 1 · 2025 · Inggris · DOAJ Scopus

    Abstract Background Immunotherapy in the presence of COVID-19 infections raises concerns because of potential overlapping clinical complications and immune system enhancement. Further investigation is warranted to establish its safety and to improve clinical decisions. Methods We conducted a…

  5. Artikel Jurnal

    Do all patients with HER2 positive breast cancer require one year of adjuvant trastuzumab? A systematic review and meta-analysis

    Paul Stewart; Phillip Blanchette; Prakesh S. Shah dkk.

    Breast, Vol. 54 · 2020 · Inggris · DOAJ Scopus

    One year of adjuvant trastuzumab is considered the standard treatment for patients with HER2 positive breast cancer. However, a shorter duration of trastuzumab may be associated with reduced costs and side effects. Results from randomized trials with diverse non-inferiority margins comparing one…

  6. Artikel Jurnal Teks lengkap

    A Multi-Centre Randomized Study Comparing Two Standard of Care Chemotherapy Regimens for Lower-Risk HER2-Positive Breast Cancer

    Ricardo Fernandes; Terry L. Ng; Mashari Jemaan Alzahrani dkk.

    Current Oncology, Vol. 30 No. 8 · 2023 · Inggris · DOAJ Scopus

    Background: Neither paclitaxel plus trastuzumab (P-H) nor docetaxel-cyclophosphamide plus trastuzumab (TC-H) have been prospectively compared in HER2-positive early-stage breast cancer (EBC). A randomized trial was performed to assess the feasibility of a larger study. Methods: Lower-risk…

  7. Artikel Jurnal

    The association between endocrine therapy use and osteoporotic fracture among post-menopausal women treated for early-stage breast cancer in Ontario, Canada

    Phillip S. Blanchette; Melody Lam; Britney Le dkk.

    Breast, Vol. 60 · 2021 · Inggris · DOAJ Scopus

    Background: The use of endocrine therapy for early-stage breast cancer, particularly aromatase inhibitor therapy has been associated with an increased risk of osteoporosis and fracture in clinical trials. We sought to validate this observation in real-world practice. Methods: We used health…

  8. Artikel Jurnal

    The quality of life in neoadjuvant versus adjuvant therapy of esophageal cancer treatment trial (QUINTETT): Randomized parallel clinical superiority trial

    Richard A. Malthaner; Edward Yu; Michael Sanatani dkk.

    Thoracic Cancer, Vol. 13 No. 13 · 2022 · Inggris · DOAJ Scopus

    Abstract Background We compared the health‐related quality of life (HRQOL) in patients undergoing trimodality therapy for resectable stage I‐III esophageal cancer. Methods A total of 96 patients were randomized to standard neoadjuvant cisplatin and 5‐fluorouracil chemotherapy plus radiotherapy…

  9. Artikel Jurnal

    Circulating tumor cells detected in follow-up predict survival outcomes in tri-modality management of advanced non-metastatic esophageal cancer: a secondary analysis of the QUINTETT randomized trial

    Edward Yu; Alison L. Allan; Michael Sanatani dkk.

    BMC Cancer, Vol. 22 No. 1 · 2022 · Inggris · DOAJ Scopus

    Abstract Background Our aim was to establish if presence of circulating tumor cells (CTCs) predicted worse outcome in patients with non-metastatic esophageal cancer undergoing tri-modality therapy. Methods We prospectively collected CTC data from patients with operable non-metastatic esophageal…